Skip to content

The latest company news, press releases, and resources about Servier and everything our company has to offer.

Advanced Search
  • servier logo
     
    06.01.2026
    Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
  • servier logo
     
    06.01.2026
    Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business
  • servier logo
     
    05.31.2026
    Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
  • servier logo
     
    05.21.2026
    Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
  • servier logo
     
    05.12.2026
    Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)
Show 5102550100 per page
Media Contacts

Servier Media Relations
us2mediarelations@servier.com

Subscribe